Market Overview

UPDATE: Bank of America Downgrades Humana to Neutral on Reimbursement Headwinds

Share:
Related HUM
Healthways Up 100% In The Last Month, But UBS Says Sell
Argus Talks Humana-Aetna Deal Uncertainty, Raises EPS Estimates For Humana
Monopoly worries surface from health insurer pullback (Seeking Alpha)

Bank of America lowered its rating on Humana (NYSE: HUM) from Buy to Neutral and reduced its price objective from $89 to $83.

Bank of America noted, "The operating environment will be more difficult for MA plans under HC Reform and the reimbursement outlook in 2014 and 2015 create significant headwinds during a time period where cost trend is not likely to be as modest as it has been over the past few years, reducing the company's margin for error. However, we expect 2013 guidance has reset the bar low and given HUM's scale and track record, we believe that they will weather this storm better than most."

Humana closed at $76.16 on Tuesday.

Latest Ratings for HUM

DateFirmActionFromTo
Aug 2016Credit SuisseMaintainsNeutral
Aug 2016JefferiesMaintainsBuy
Aug 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!